Founded in 2015, Evelo has established a therapeutics platform based on the human immuno-microbiome. The company holds a worldwide exclusive license to this technology from the University of Chicago. The platform targets an underserved therapeutic intersection of immunology and microbiology with potential for orally delivered, affordable therapies.
Cyborg Score Rationale
Evelo operates in a scientifically defensible but capital-intensive space with multiple clinical-stage programs and published science backing. However, the company remains early-stage with limited revenue, modest employee count (approximately 19–66 depending on source), and typical biotech execution risk. No recent material catalysts or funding announcements are evident in 2026.
Top Insights
Platform is unique oral microbe-based therapeutic approach (monoclonal microbials) with exclusive University of Chicago IP, differentiating from antibody and small-molecule competitors
Clinical-stage with four product candidates: EDP1815 and EDP1867 in inflammatory diseases, EDP2939 in psoriasis, and EDP1908 in oncology
Minimal reported revenue (~$1.5M–$25.8M depending on data source) indicates early funding/grant dependency with no commercial products on market
Public company (NASDAQ: EVLO) provides access to capital markets but must meet ongoing disclosure requirements and clinical milestone expectations
Named Competitors
Inovio Pharmaceuticals — Immunotherapy and vaccine development
Rgenix — Microbiome-derived therapeutics for immunology
Seres Therapeutics — Microbiome therapeutics for inflammatory and oncology indications
Recent Developments
EDP1815 advanced to Phase 2 trials for psoriasis and atopic dermatitis
EDP1867 in Phase 1b clinical trial
CFO Marella Thorell appointed (September 2022)
Open the full interactive Evelo Biosciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.